All News

The FDA recently added famotidine to its list of drug shortages.

Today, the American Society of Health-System Pharmacists (ASHP) sent a letter to Vice President Mike Pence to urge the transparent and orderly allocation of remdesivir among hospitals

A new study suggests that well-controlled blood sugar may reduce mortality for patients with diabetes and COVID-19.

Officials with the FDA have approved celecoxib oral solution 25 mg/mL (Elyxyb, Dr. Reddy’s Laboratories) for the acute treatment of migraine with or without aura in adults.

Capmatinib (Tabrecta, Novartis) is a kinase inhibitor effective in blocking a key enzyme, resulting in decelerated tumor cell growth.

Results of the study showed that antihypertensive medications do not put individuals at increased risk for COVID-19.

The National Association of Specialty Pharmacy has announced that former interim chair of the Democratic National Committee Donna Brazile and former chairman of the Republican National Committee Michael Steele will give a joint keynote presentation on the political landscape, election 2020, and the future of their respective parties.

Roche received FDA Emergency Use Authorization for its anti-SARS-CoV-2 antibody test, Elecsys.

Devin English, assistant professor at Rutgers School of Health, joined Drug Topics® to discuss how COVID-19 is disproportionately affecting minorities, the history that explains this trend, and the issues that will remain after the pandemic ends.

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

The study warned that, with 74 million children in the United States, PICU resources could face concerning strain from COVID-19.

A new study evaluated methods of improving heart function in individuals with type 2 diabetes.

A case report from NYU Langone Health assessed the use of both urgent and non-urgent telemedicine visits.

Officials with the FDA have issued an emergency use authorization for remdesivir (Gilead Sciences) for the treatment of suspected or laboratory-confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and children. 

Here's a roundup of this week's coronavirus-related news.

In part 2 of our interview, Aman Brar, chief executive officer of Jobvite, discussed with Drug Topics® how recruiting software is transforming the hiring process during the coronavirus disease 2019 pandemic.

In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.

Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.

Americans are increasingly concerned about drug shortages due to the coronavirus disease 2019 (COVID-19) pandemic, according to a new survey by prescription savings service SingleCare.

The campaign will feature testimonials from patients of the COVID-19 pandemic’s “unsung heroes.”

A recent study included interviews with pharmacists in rural Kentucky counties regarding pharmacy-level barriers to opioid use disorder treatment.

One out of 7 US adults reported that they would avoid seeking health care for a fever and dry cough for fear of not being able to pay for it.

In a presidential Coronavirus Task Force briefing, NACDS affirmed the indispensable role of pharmacists during the COVID-19 pandemic.

Building literature evaluation skills is an essential teaching component during all stages of pharmacy education

Aman Brar, chief executive officer of Jobvite, discussed with Drug Topics® how recruiting software is transforming the hiring process during the coronavirus disease 2019 pandemic.

The quadrivalent meningococcal vaccine is indicated persons 2 years of age and older in the United States.

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

115 members of the House have come out in support of eliminating DIR fees in future coronavirus relief packages.